Review
Chemistry, Multidisciplinary
Yunfei Yi, Mian Yu, Wen Li, Dunwan Zhu, Lin Mei, Meitong Ou
Summary: The development of therapeutic cancer vaccines using nanotechnology has great potential in improving the limitations of current immunotherapies. Nanoparticles enhance vaccine stability and antigen recognition through their small size, while surface modifications allow targeted delivery. Nanocarriers with adjuvant effect also improve vaccine efficacy. Additionally, nanoparticle-mediated chemotherapy and radiotherapy induce the release of tumor antigens, simulating anti-tumor immune responses. These vaccine-like nanomedicines can effectively eliminate tumors and prevent recurrence and metastasis. This article presents recent advancements in nanoparticle-based antigen delivery for in situ anti-tumor vaccination and discusses the remaining opportunities and challenges for clinical translation.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Biochemistry & Molecular Biology
Elham Mahdevar, Ashkan Safavi, Ardavan Abiri, Amirhosein Kefayat, Seyed Hossein Hejazi, Seyed Mohsen Miresmaeili, Vahid Iranpur Mobarakeh
Summary: A novel multi-epitope vaccine against breast cancer was designed using immunoinformatics approaches and computational methods, showing stability and immunogenicity with approximately 93% to 96% global population coverage for HLA-I and HLA-II. These preliminary results provide a suitable platform for further experimental investigations.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
Review
Materials Science, Biomaterials
Nian Liu, Xiangyu Xiao, Ziqiang Zhang, Chun Mao, Mimi Wan, Jian Shen
Summary: Cancer vaccines are a promising therapeutic strategy in clinical oncology, stimulating antitumor immunity to fight against cancer. However, there are several challenges that hinder their broad clinical translation.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2023)
Article
Biochemistry & Molecular Biology
Dandan Li, Lingyun Xia, Pan Huang, Zidi Wang, Qiwei Guo, Congcong Huang, Weidong Leng, Shanshan Qin
Summary: In this study, PRSS56, a testis-specific serine protease, was identified as a novel cancer/testis antigen. PRSS56 was frequently overexpressed in various cancers, especially in gastrointestinal cancer. The expression of PRSS56 was associated with DNA methylation levels, and its decreased methylation led to overexpression in GC and CRC. Furthermore, PRSS56 activated the oncogenic PI3K/AKT signaling pathway in GC and CRC.
CELL AND BIOSCIENCE
(2023)
Article
Biotechnology & Applied Microbiology
Ashkan Safavi, Amirhosein Kefayat, Elham Mahdevar, Fatemeh Ghahremani, Navid Nezafat, Mohammad Hossein Modarressi
Summary: The study demonstrated that prophylactic co-immunization with multiepitope DNA and peptide cancer vaccines can significantly enhance the immune response against breast cancer, leading to reduced tumor volume and increased survival time in tumor-bearing mice. Further experiments are needed to evaluate their efficacy from different angles.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Oncology
Jie Wang, Kaichen Zhou, Huihuang Zhu, Fukun Wei, Sai Ma, Yi Kan, Bingheng Li, Lijun Mao
Summary: Currently, common treatments for prostate cancer include surgery, radiation therapy, chemotherapy, and hormone therapy. However, patients often experience high recurrence rates and may develop castration-resistant prostate cancer. Tumor vaccines, which utilize tumor-specific antigens (TSA) and tumor-associated antigens (TAA), aim to activate a specific immune response against cancer cells in the body. Different types of prostate cancer vaccines, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines, have been developed with the advancement of tumor vaccine technology. This review provides a summary of the current status and progress in the development of prostate cancer vaccines.
Review
Genetics & Heredity
Reihaneh Alsadat Mahmoudian, Maharati Amirhosein, Parvaneh Mahmoudian, Fatemeh Fardi Golyan, Leila Mokhlessi, Mina Maftooh, Majid Khazaei, Mohammadreza Nassiri, Seyed Mahdi Hassanian, Majid Ghayour-Mobarhan, Gordon Ferns, Soodabeh Shahidsales, Amir Avan
Summary: Gastric cancer is a leading cause of mortality globally and presents challenges in diagnosis, prognosis, and therapy. Cancer-testis antigens (CTAs) have been identified as potential biomarkers and targets for cancer immunotherapy. Numerous studies have reported the dysregulation of CTAs in gastric cancer, and clinical trials have been conducted to evaluate their immunotherapeutic potential.
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Biochemistry & Molecular Biology
Farzana Hossain, Shruthi Kandalai, Xiaozhuang Zhou, Nan Zhang, Qingfei Zheng
Summary: In this review, synthetic approaches for antigen-based cancer vaccines are highlighted, along with the discussion of various bioconjugation strategies. The progress of genetically modified cancer vaccines in clinical research is also summarized. Additionally, the synthesis of adjuvants and utilization of biomaterial scaffolds for enhancing immune responses are mentioned.
Article
Chemistry, Multidisciplinary
Dandan Han, Fei Wang, Yichuan Ma, Yu Zhao, Wei Zhang, Ziyang Zhang, Huifang Liu, Xinjian Yang, Chi Zhang, Jinchao Zhang, Zhenhua Li
Summary: This study explores the use of engineered photosynthetic bacteria and outer membrane vesicles to enhance cancer immunotherapy. By capturing and transporting tumor antigens to the outer regions of the tumor, the researchers were able to promote efficient antigen presentation and trigger potent antitumor immune responses. This approach shows promising potential in the development of personalized cancer vaccination strategies.
Article
Immunology
Xin Zhang, Yanlong Zhang, Li Zhao, Jiayu Wang, Jiaxing Li, Xi Wang, Min Zhang, Xiaopeng Hu
Summary: This study identified potential tumor antigens for mRNA vaccines in bladder cancer (BLCA) and defined three immune subtypes in BLCA. It also applied the immcluster package to predict suitable BLCA patients for antitumor therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liza O'Donnell, Diane Rebourcet, Laura F. Dagley, Raouda Sgaier, Giuseppe Infusini, Peter J. O'Shaughnessy, Frederic Chalmel, Daniela Fietz, Wolfgang Weidner, Julien M. D. Legrand, Robin M. Hobbs, Robert McLachlan, Andrew Webb, Adrian Pilatz, Thorsten Diemer, Lee B. Smith, Peter G. Stanton
Summary: A wide range of germ cell-derived and sperm-specific proteins can access the circulatory- and immune systems, potentially impacting male fertility and serving as candidates for cancer immunotherapy. The abundance of these proteins in testicular interstitial fluid may depend on fertility status, suggesting implications for male infertility management and cancer treatment.
Review
Immunology
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan
Summary: Immunotherapy has emerged as a breakthrough in cancer treatment, and mRNA vaccines have shown great potential in cancer immunotherapy. Recent technological advances have accelerated the development and application of mRNA cancer vaccines. This review highlights various cancer vaccine platforms, focusing on nucleic acid vaccines, and discusses the design and delivery strategies for mRNA cancer vaccines, as well as the limitations and future challenges.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Yu Zhao, Bo Han, Jialei Hao, Yadan Zheng, Jingshan Chai, Zhanzhan Zhang, Yang Liu, Linqi Shi
Summary: The bi-specific macrophage nano-engager (BiME) enhances the recognition and phagocytosis of tumor cells by macrophages, achieving effective tumor-associated antigen (TAA) uptake and presentation to activate antitumor responses. BiME converts tumor cells into an in situ vaccine, triggering robust T cell-dependent antitumor responses, and could potentially be a universal strategy for enhancing antitumor immunity against a broad range of solid tumors.
Article
Engineering, Biomedical
Huijuan Song, Qi Su, Yu Nie, Chuangnian Zhang, Pingsheng Huang, Shengbin Shi, Qiang Liu, Weiwei Wang
Summary: Vaccination has shown great potential in cancer immunotherapy, but achieving strong and broad therapeutic CD8 T cell immunity against tumors is challenging due to tumor heterogeneity. In this study, a bioinspired nanofibrous trivalent peptide hydrogel vaccine was constructed to mimic the structure and function of the extracellular matrix. The vaccine effectively stimulated CD8 T cell response and inhibited tumor growth in mice. This approach offers a simple and versatile platform for the development of personalized cancer vaccines.
ACTA BIOMATERIALIA
(2023)
Article
Multidisciplinary Sciences
Yao-Tseng Chen, Amy Chadburn, Peishan Lee, Melinda Hsu, Erika Ritter, April Chiu, Sacha Gnjatic, Michael Pfreundschuh, Daniel M. Knowles, Lloyd J. Old
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2010)
Article
Respiratory System
Melinda L. Hsu, Jarushka Naidoo
THORACIC SURGERY CLINICS
(2020)
Article
Oncology
Aanika Balaji, Melinda Hsu, Cheng Ting Lin, Josephine Feliciano, Kristen Marrone, Julie R. Brahmer, Patrick M. Forde, Christine Hann, Lei Zheng, Valerie Lee, Peter B. Illei, Sonye K. Danoff, Karthik Suresh, Jarushka Naidoo
Summary: Steroid-refractory ICI-pneumonitis accounted for 18.5% of multidisciplinary irAE care referrals. This condition often occurred early in patients' treatment courses and most commonly presented with a diffuse alveolar damage (DAD) radiographic pattern. Patients treated with IVIG alone showed improvement in level-of-care and oxygenation requirements, with lower fatality rates (43%) compared to those treated with infliximab (100% mortality).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Meeting Abstract
Oncology
Paola Ghanem, Joseph Murray, Melinda Hsu, David Ettinger, Josephine Feliciano, Patrick Forde, Christine Hann, Vincent Lam, Benjamin Levy, Julie Brahmer, Kristen Marrone
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Laura A. Sena, Ramy Sedhom, Susan Scott, Amanda Kagan, Andrew H. Marple, Jenna Canzoniero, Melinda Hsu, Syed M. Qasim Hussaini, Amin S. Herati, Lauren Reschke, Maria Facadio Antero, Mindy S. Christianson, Adam F. Binder, Allen R. Chen, Ross C. Donehower, Kristen A. Marrone, Arjun Gupta
Summary: The study aimed to increase oncofertility counseling rates for reproductive-aged cancer patients. By forming a team, identifying barriers, and implementing improvement plans, significant progress was achieved.
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Melinda L. Hsu, Joseph C. Murray, Kevin J. Psoter, Jiajia Zhang, Durrant Barasa, Julie R. Brahmer, David S. Ettinger, Patrick M. Forde, Christine L. Hann, Vincent K. Lam, Benjamin Levy, Kristen A. Marrone, Tricia Patel, Valerie Peterson, Sarah Sagorsky, Michelle Turner, Valsamo Anagnostou, Jarushka Naidoo, Josephine L. Feliciano
Summary: This study identifies a significant proportion of survivors of non-small cell lung cancer (NSCLC) treated with anti-PD-(L)1 immune checkpoint inhibitors (ICI) who experience unresolved long-term toxicities. These findings highlight the need to better understand long-term toxicities in order to optimize the management of patients treated with ICIs.